ProQR Therapeutics (PRQR) Capital Expenditures Growth (3y) (2016 - 2026)
ProQR Therapeutics (PRQR) Capital Expenditures Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 16.27% |
| 10 | ProQR Therapeutics | 181.75 Mn | 89.46 Mn | - | 47.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.45% |
| Dec 31, 2025 | 1.94% |
| Sep 30, 2025 | 11.76% |
| Jun 30, 2025 | 34.58% |
| Mar 31, 2025 | -2.81% |
| Dec 31, 2024 | 141.09% |
| Sep 30, 2024 | -17.79% |
| Jun 30, 2024 | 92.51% |
| Mar 31, 2024 | -183.87% |
| Dec 31, 2023 | 172.05% |
| Sep 30, 2023 | -8.69% |
| Jun 30, 2023 | 5.10% |
| Mar 31, 2023 | -782.32% |
| Dec 31, 2022 | 99.83% |
| Sep 30, 2022 | -97.36% |
| Jun 30, 2022 | -39.01% |
| Mar 31, 2022 | 45.72% |
| Dec 31, 2021 | -1,927.40% |
| Sep 30, 2021 | -11.70% |
| Jun 30, 2021 | 39.15% |